SCHEMBL4674644

SCHEMBL4674644

O=C(Cc1sccc1S(=O)(=O)c1ccccc1)C(=O)c1nn[nH]n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 1/20 0.43
ALDH1A1 P00352 2/20 0.36
CES1 P23141 1/20 0.36
NCEH1 Q6PIU2 1/20 0.36
POLB P06746 1/20 0.34
ERCC5 P28715 1/20 0.34
FEN1 P39748 1/20 0.34
MMP2 P08253 4/20 0.33
MMP12 P39900 4/20 0.33
MMP13 P45452 4/20 0.33
MMP14 P50281 4/20 0.33
MMP1 P03956 3/20 0.33
MMP3 P08254 3/20 0.33
MMP9 P14780 3/20 0.33
MMP8 P22894 3/20 0.33
MMP16 P51512 3/20 0.33
RECQL P46063 1/20 0.33
KDM4E B2RXH2 1/20 0.33
HDAC3 O15379 1/20 0.32
HDAC4 P56524 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4672385 0.90 MMP1 (0.35) NPSR1MMP2MMP12MMP13MMP14
SCHEMBL4675882 0.90 CXCR3 (0.35) NPSR1ALDH1A1POLBKMT2AHTT
SCHEMBL4677580 0.82 CES1 (0.36) NPSR1ALDH1A1CES1NCEH1POLB
SCHEMBL4674637 0.82 NPSR1 (0.43) NPSR1ALDH1A1POLBMMP2MMP12
SCHEMBL4675843 0.80 MMP2 (0.36) NPSR1ALDH1A1CES1NCEH1ERCC5
SCHEMBL4677823 0.80 MMP2 (0.37) ALDH1A1CES1NCEH1ERCC5FEN1
SCHEMBL4674397 0.79 HDAC3 (0.39) ALDH1A1CES1NCEH1ERCC5FEN1
SCHEMBL5899367 0.79 CES1 (0.36) NPSR1ALDH1A1CES1NCEH1ERCC5
SCHEMBL4675587 0.78 LOX (0.39) ALDH1A1CES1NCEH1POLBERCC5
SCHEMBL4671660 0.78 MMP2 (0.36) ALDH1A1CES1NCEH1ERCC5FEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
CN-1335834-A Aromatic heterocyclic compounds having HIV integrase inhibitory activity SHIONOGI & CO (JP) 2002-02-13 CN disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 NPSR1 937/4885ALDH1A1 980/4885CES1 445/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.